Navigation Links
Covance Board Authorizes $100 Million Stock Buyback
Date:12/19/2013

PRINCETON, N.J., Dec. 19, 2013 /PRNewswire/ -- Covance Inc. (NYSE: CVD) said today that its Board of Directors has authorized the repurchase of up to $100 million of its outstanding common stock.  Any purchases under this buyback would be dependent upon business and market conditions and other factors.  The stock purchases may be made from time to time and may be made through a variety of methods including open market purchases, privately negotiated transactions, block trades, and 10b5-1 plans.

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $2.2 billion and more than 12,000 employees located in over 60 countries.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements including the statements contained herein regarding anticipated trends in the company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories,  fluctuations in currency exchange rates, the realization of savings from the company's announced restructuring actions, the cost and pace of completion of our information technology projects and the realization of benefits therefrom,  the satisfaction of the conditions of the note purchase agreement and the closing thereof, and other factors described in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company's expectations.


'/>"/>
SOURCE Covance Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Covance Central Laboratories and NeoGenomics Enter into Exclusive Alliance to Provide Comprehensive Anatomic Pathology, Histology and Specialty Laboratory Testing Services for Clinical Trials
2. Covance To Present At The Credit Suisse Healthcare Conference
3. Covance Reports Third Quarter Net Revenue Of $607 Million, Pro Forma EPS Of $0.83 And Adjusted Net Orders Of $732 Million
4. Covance Launches Managed Markets Services
5. Financial Results, Earnings Schedules, Quarterly Dividends, and Top Rankings - Research Report on Quest Diagnostics, PerkinElmer, PAREXEL, Covance, and ICON
6. Covance Inc. Invites You to Join the Webcast of Its Second Quarter 2013 Financial Results Conference Call
7. Covance Reports Second Quarter Net Revenue of $592 Million, Pro Forma EPS of $0.78 and Record Adjusted Net Orders of $776 Million
8. Covance Central Laboratory Services Again Ranks #1 in Global Investigator Satisfaction Survey
9. Covance To Present At The Goldman Sachs 34th Annual Global Healthcare Conference
10. Covance Reports First Quarter Net Revenue Growth Of 9.3% To $580 Million, Pro Forma EPS Of $0.75 And Adjusted Net Orders Of $716 Million
11. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)...  Ethicon* today announced the completion of its ... medical device company that manufactures and markets the ... of Gastroesophageal Reflux Disease (GERD). This acquisition is ... of minimally invasive options for patients suffering from ... the transaction have not been disclosed. ...
(Date:3/23/2017)... A research report by Mordor Intelligence ... reach USD 7.2 billion by the end of 2021 and ... procedure in which a sample is preserved prior to its ... since the methods are often allowing repeated testing. The report ... shared procedures in the lab. In many life science labs, ...
(Date:3/23/2017)... DENVER , March 23, 2017  Drug ... pain medication misuse and deadly overdoses. A new ... Health Solutions, www.cordantsolutions.com , reports more detailed ... tests, which can potentially improve therapy adherence, patient ... The Cordant Comprehensive Oral fluid Rx Evaluation ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A ... minister and college Bible teacher residing in North Carolina with his wife, Anna Marie. ... blessed them with six grandchildren. David is also the author of “Shadow and Substance.” ...
(Date:3/23/2017)... WA (PRWEB) , ... March 23, 2017 , ... In ... and now estimates that there could be four million Zika-related cases in the Americas ... date with numbers of US cases reported per year skyrocketing to an estimated 329,000. ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to improving ... health departments have been awarded national accreditation through the Public Health Accreditation ... expanding network of communities across the nation whose health departments meet rigorous national ...
(Date:3/23/2017)... ... ... The IoT (Internet of Things) is revolutionizing the way the world operates. ... and individual consumers alike. Laboratories can maximize their profit margin by increasing throughput. ... trillion to $11 trillion dollars by the year 2025. McKinsey expects the IoT to ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... and businesses of the Norwalk and Vermillion areas, celebrates the newest charity ... is a nonprofit, community-based substance abuse prevention and peer recovery support organization ...
Breaking Medicine News(10 mins):